{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:57Z","timestamp":1786118937745,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1097\/fpc.0b013e3282f01aa3","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T08:41:41Z","timestamp":1209890501000},"page":"989-993","source":"Crossref","is-referenced-by-count":33,"title":["CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine"],"prefix":"10.1097","volume":"17","author":[{"given":"Eleni","family":"Aklillu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kalow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Endrenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vural","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210212","first-page":"S235","article-title":"Atypical antipsychotics and the burden of disease","volume":"11 (Suppl 8)","author":"Simpson","year":"2005","journal-title":"Am J Manag Care"},{"key":"R2-9-20210212","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00004714-198806000-00008","article-title":"Haloperidol and prolactin concentrations in Asians and Caucasians","volume":"8","author":"Lin","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"R3-9-20210212","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/14656566.7.2.119","article-title":"Pharmacogenetics for off-patent antipsychotics: re-defining the risk for tardive dyskinesia and access to essential medicines","volume":"7","author":"Ozdemir","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"R4-9-20210212","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R5-9-20210212","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00213-006-0622-x","article-title":"Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients","volume":"190","author":"Gunes","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R6-9-20210212","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajmg.1303","article-title":"Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol","volume":"105","author":"Mihara","year":"2001","journal-title":"Am J Med Genet Part B"},{"key":"R7-9-20210212","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.coph.2003.09.007","article-title":"Pharmacogenetics and psychopharmacology","volume":"4","author":"Bondy","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"R8-9-20210212","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrd1801","article-title":"Pharmacogenetics-based therapeutic recommendations \u2013 ready for clinical practice?","volume":"4","author":"Kirchheiner","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"R10-9-20210212","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s002139900364","article-title":"Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene","volume":"149","author":"Mihara","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R11-9-20210212","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","article-title":"Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele","volume":"185","author":"Young","year":"2004","journal-title":"Br J Psychiatry"},{"key":"R12-9-20210212","first-page":"778","article-title":"The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP","volume":"45","author":"Grandy","year":"1989","journal-title":"Am J Hum Genet"},{"key":"R13-9-20210212","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/geno.1998.5264","article-title":"DRD2 allele frequencies and linkage disequilibria, including the -141CIns\/Del promoter polymorphism, in European-American, African-American, and Japanese subjects","volume":"51","author":"Gelernter","year":"1998","journal-title":"Genomics"},{"key":"R14-9-20210212","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1021648128758","article-title":"Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics","volume":"28","author":"Ritchie","year":"2003","journal-title":"Neurochem Res"},{"key":"R15-9-20210212","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.mp.4000350","article-title":"The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers","volume":"3","author":"Pohjalainen","year":"1998","journal-title":"Mol Psychiatry"},{"key":"R16-9-20210212","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","article-title":"D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele","volume":"7","author":"Thompson","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R17-9-20210212","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0888-7543(91)90431-D","article-title":"Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene","volume":"10","author":"Hauge","year":"1991","journal-title":"Genomics"},{"key":"R18-9-20210212","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/1531-8257(200001)15:1<120::AID-MDS1019>3.0.CO;2-S","article-title":"The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease","volume":"15","author":"Oliveri","year":"2000","journal-title":"Mov Disord"},{"key":"R19-9-20210212","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/hmg\/6.4.577","article-title":"A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia","volume":"6","author":"Arinami","year":"1997","journal-title":"Hum Mol Genet"},{"key":"R20-9-20210212","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.mp.4000532","article-title":"Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers","volume":"4","author":"Jonsson","year":"1999","journal-title":"Mol Psychiatry"},{"key":"R21-9-20210212","doi-asserted-by":"crossref","first-page":"26013","DOI":"10.1074\/jbc.271.42.26013","article-title":"Functional analysis of the human D2 dopamine receptor missense variants","volume":"271","author":"Cravchik","year":"1996","journal-title":"J Biol Chem"},{"key":"R22-9-20210212","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1081\/DMR-120034000","article-title":"Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates","volume":"36","author":"Yu","year":"2004","journal-title":"Drug Metab Rev"},{"key":"R23-9-20210212","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FPC.0b013e32801a3c10","article-title":"CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk re-visited","volume":"17","author":"Ozdemir","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"R24-9-20210212","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.npp.1300919","article-title":"Polymorphisms in the 5-hydroxytryptamine 2A receptor and Cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients","volume":"31","author":"Suzuki","year":"2006","journal-title":"Neuropsychopharmacol"},{"key":"R25-9-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R26-9-20210212","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5414\/CPP43163","article-title":"Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients","volume":"43","author":"Nakazono","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R27-9-20210212","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01.fpc.0000167331.30905.9e","article-title":"Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets","volume":"15","author":"Kirchheiner","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R28-9-20210212","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ajmg.b.10005","article-title":"D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes","volume":"116","author":"Noble","year":"2003","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R29-9-20210212","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/07420520701282349","article-title":"Possible linkage between the ability to change the period (tau) of the prolactin and cortisol rhythms in women and breast cancer risk","volume":"24","author":"Lewy","year":"2007","journal-title":"Chronobiol Int"},{"key":"R30-9-20210212","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1191\/0960327106ht643oa","article-title":"Hyperprolactinemia as an adverse effect in regulatory and clinical toxicology: role in breast cancer and prostate cancer","volume":"25","author":"Harvey","year":"2006","journal-title":"Hum Exp Toxicol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0b013e3282f01aa3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:06:23Z","timestamp":1786035983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01213011-200711000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e3282f01aa3","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}